文献速递骨质疏松与钙磷/甲状旁腺

血清1,25-二羟维生素D作为术后甲状旁腺功能减退症无高钙尿症的生物标志物

Serum 1,25-Dihydroxyvitamin D as a Biomarker of the Absence of Hypercalciuria in Postsurgical Hypoparathyroidism.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

本研究为前瞻性横断面研究,纳入34例接受口服钙和骨化三醇治疗的永久性术后甲状旁腺功能减退症稳定门诊患者(共54次观察)及17名无甲状旁腺功能减退的成人对照。无高钙尿症组(n=21)血清1,25-二羟维生素D水平低于高钙尿症组(n=33)(33.5 ± 11.9 pg/mL vs 45.8 ± 9.5 pg/mL;P < 0.001)。血清1,25-二羟维生素D预测无高钙尿症的切点值为33.5 pg/mL,灵敏度100%、特异度63.6%,AUC为0.797;血清1,25-二羟维生素D <33.5 pg/mL的患者均无高钙尿症。

要点

  • 无高钙尿症组血清1,25-二羟维生素D为33.5 ± 11.9 pg/mL,低于高钙尿症组的45.8 ± 9.5 pg/mL(P < 0.001)。
  • 血清1,25-二羟维生素D预测无高钙尿症的切点值为33.5 pg/mL,灵敏度100%、特异度63.6%,AUC为0.797。
  • 血清1,25-二羟维生素D <33.5 pg/mL的患者均无高钙尿症,与白蛋白校正血清钙水平无关。

核心结论

  • 常规检测血清1,25-二羟维生素D可能有助于预测接受口服钙和骨化三醇治疗的永久性术后甲状旁腺功能减退症患者无高钙尿症。

研究设计与样本

  • 前瞻性横断面研究,纳入34例接受口服钙和骨化三醇治疗的永久性术后甲状旁腺功能减退症稳定门诊患者(共54次连续观察)及17名无甲状旁腺功能减退的成人对照,无干预措施。

主要发现

  • 无高钙尿症组(n=21)血清1,25-二羟维生素D为33.5 ± 11.9 pg/mL,低于高钙尿症组(n=33)的45.8 ± 9.5 pg/mL(P < 0.001)。
  • 无高钙尿症组与高钙尿症组白蛋白校正血清钙分别为8.3 ± 0.5 mg/dL与8.6 ± 0.5 mg/dL(P = nonsignificant),血清甲状旁腺激素分别为12.5 ± 5.7 pg/mL与10.7 ± 6.8 pg/mL(P = nonsignificant)。
  • 多元线性回归分析显示1,25-二羟维生素D与尿钙排泄独立相关(B = 6.2 ± 1.423;P < 0.001)。
  • 血清1,25-二羟维生素D预测无高钙尿症的切点值为33.5 pg/mL,灵敏度100%、特异度63.6%,受试者工作特征曲线下面积为0.797。
  • 血清1,25-二羟维生素D <33.5 pg/mL的患者均无高钙尿症,与白蛋白校正血清钙水平无关。

关键数值与推荐

  • 高钙尿症定义为24小时尿钙 >300 mg。
  • 血清1,25-二羟维生素D预测无高钙尿症的切点值为33.5 pg/mL,灵敏度100%、特异度63.6%,AUC为0.797。

临床怎么用

  • 作者认为,常规检测血清1,25-二羟维生素D可能有助于预测接受口服钙和骨化三醇治疗的永久性术后甲状旁腺功能减退症患者无高钙尿症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hypercalciuria is an adverse event of postsurgical hypoparathyroidism treatment that can lead to renal complications. The collection of 24-hour urine to detect hypercalciuria is often considered unreliable. OBJECTIVE: The purpose of this study was to find useful predictive biomarkers of hypercalciuria in patients with permanent postsurgical hypoparathyroidism receiving treatment with oral calcium and calcitriol supplements. DESIGN AND SETTING: The investigation was designed as a prospective cross-sectional study. An outpatient hospital clinic served as the study setting. PATIENTS: Fifty-four consecutive observations were made of 34 stable outpatients with postsurgical hypoparathyroidism taking oral calcium and calcitriol supplements, and 17 adult controls without hypoparathyroidism. INTERVENTION: There were no interventions. MAIN OUTCOME MEASURE: Hypercalciuria was defined as 24-hour urine calcium >300 mg. RESULTS: Patients without hypercalciuria (n = 21) vs those with hypercalciuria (n = 33) had lower levels of serum 1,25-dihydroxyvitamin D (33.5 ± 11.9 pg/mL vs 45.8 ± 9.5 pg/mL; P < 0.001), similar albumin-corrected serum calcium (8.3 ± 0.5 vs 8.6 ± 0.5 mg/dL; P = nonsignificant), and serum parathyroid hormone (12.5 ± 5.7 vs 10.7 ± 6.8 pg/mL; P = nonsignificant). Multiple linear regression analysis showed an independent relationship between 1,25-dihydroxyvitamin D and urinary calcium excretion (B = 6.2 ± 1.423; P < 0.001). A cutoff value of 33.5 pg/mL for serum 1,25-dihydroxyvitamin D to predict the absence of hypercalciuria had 100% sensitivity and 63.6% specificity, and the area under the receiver operating characteristic curve was 0.797. No patients with serum 1,25-dihydroxyvitamin D levels of <33.5 pg/mL presented with hypercalciuria, regardless of the level of albumin-corrected serum calcium. CONCLUSIONS: Routine measurement of serum 1,25-dihydroxyvitamin D may be useful as a biomarker to predict the absence of hypercalciuria in patients with permanent postsurgical hypoparathyroidism who are receiving treatment with oral calcium and calcitriol supplements.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. García-Pascual L, Barahona MJ, Perea V, et al. Serum 1,25-Dihydroxyvitamin D as a Biomarker of the Absence of Hypercalciuria in Postsurgical Hypoparathyroidism. J Clin Endocrinol Metab. 2017. PMID: 27813709. doi:10.1210/jc.2016-2987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。